M2 TAMs offer hepatocyte growth factor (HGF) to activate the HGF/c‐Met, ERK1/2/MAPK, and PI3K/AKT pathways, enlisting more macrophages to tumor tissue and intensifying HCC resistance to sorafenib in a pre‐feedback manner.51 The gene discussed is HGF; the disease is neoplasm.